首页> 外文期刊>Heart and vessels: An international journal >Drug-coated stent implantation vs. bypass surgery for in-stent occlusion after femoropopliteal stenting
【24h】

Drug-coated stent implantation vs. bypass surgery for in-stent occlusion after femoropopliteal stenting

机译:药物涂层支架植入术后支架闭塞术后支架闭塞术后

获取原文
获取原文并翻译 | 示例
       

摘要

The optimal revascularization for in-stent occlusion (ISO) lesions after femoropopliteal (FP) bare-nitinol stenting has not been established. We, therefore, investigated the comparison between drug-coated stent (DCS) implantation and bypass surgery (BSX) for ISO lesions after FP bare-nitinol stenting. This study was a dual-center, observational study from January 2004 to December 2015. A total of 172 ISO lesions were observed, and after excluding 120 ISO lesions, 52 ISO lesions (50 patients; mean age, 71.0 +/- 9.2 years; male, 59.6%) after FP bare-nitinol stenting were enrolled. The included patients with clinical symptoms underwent either DCS implantation (n = 28) or BSX (n = 22). The primary endpoint was recurrent in-stent restenosis (ReISR); secondary endpoints were recurrent target lesion revascularization (ReTLR), recurrent occlusion (reocclusion) and major adverse limb events (MALE), and perioperative complications (POCs), respectively. ReISR or reocclusion was defined as ISR or occlusion after TLR. Stent restenosis was defined as a peak systolic velocity ratio (PSVR) > 2.4 on a duplex scan or >= 50% stenosis on angiography. Graft restenosis was defined as a PSV > 300 cm/s and velocity ratio 3.5 or uniformly low PSV < 45 cm/s throughout the entire graft based on graft surveillance. The mean follow-up period was 36.6 +/- 25.5 months. At 2 years, the rates of freedom from ReISR, ReTLR, and MALE were not significantly different between the DCS implantation and BSX groups (68.9% vs. 73.7%, p = 0.81; 84.7% vs. 73.7%, p = 0.45; 84.7% vs. 78.6%, p = 0.60, respectively). However, the freedom from reocclusion rate was significantly lower in the DCS implantation group (81.6% vs. 100%, p = 0.04). The occurrence of POCs was not significantly different between the DCS implantation and BSX groups (7.1% vs 4.2%, p = 1.0). Although BSX was the gold-standard therapy for ISO lesions after FP bare-nitinol stenting, DCS implantation might be a good option because the rates of freedom from ReISR, ReTLR, and MALE were similar.
机译:股骨腘部(FP)裸镍钛诺支架置入术后支架内闭塞(ISO)病变的最佳血运重建尚未确定。因此,我们研究了FP裸镍钛合金支架置入术后药物涂层支架(DCS)植入和旁路手术(BSX)治疗ISO病变的比较。本研究是2004年1月至2015年12月的一项双中心观察性研究。共观察到172个ISO病变,排除120个ISO病变后,纳入FP裸镍钛合金支架置入术后52个ISO病变(50名患者;平均年龄71.0+/-9.2岁;男性59.6%)。有临床症状的患者接受DCS植入(n=28)或BSX(n=22)。主要终点为支架内再狭窄复发(ReISR);次要终点分别为复发性靶病变血运重建(ReTLR)、复发性闭塞(reocclusion)、主要肢体不良事件(男性)和围手术期并发症(POC)。ReISR或reocclusion被定义为TLR后的ISR或闭塞。支架再狭窄的定义是:双功能扫描时收缩期峰值速度比(PSVR)>2.4,或血管造影时狭窄>50%。根据移植物监测,移植物再狭窄被定义为PSV>300cm/s,速度比为3.5,或整个移植物的PSV<45cm/s均较低。平均随访时间为36.6±25.5个月。2年时,DCS植入组和BSX组的ReISR、ReTLR和男性患者的自由率没有显著差异(分别为68.9%和73.7%,p=0.81;84.7%和73.7%,p=0.45;84.7%和78.6%,p=0.60)。然而,DCS植入组的再封闭率明显较低(81.6%对100%,p=0.04)。DCS植入组和BSX组的POCs发生率无显著差异(7.1%对4.2%,p=1.0)。尽管BSX是FP裸镍钛诺支架术后ISO病变的金标准治疗方法,但DCS植入可能是一个不错的选择,因为ReISR、ReTLR和男性患者的自由率相似。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号